Charleston Laboratories, Inc. Phase I Clinical Trial
Charleston Laboratories, Inc, an emerging specialty pharmaceutical company dedicated to reducing opioid induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced the initiation of a pharmacokinetic study on its first drug candidate, CL-108. “After many months’ development in the lab, resulting in the optimal formulation of this drug, it is ready for testing in man,” said Dr. Bernard Schachtel, Chief Medical Officer at Charleston Laboratories.
More: continued here
Filed under: Pain / Anesthetics on January 16th, 2009